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Patients with community-acquired pneumonia (CAP) undergo a dysregulated host response
that is related to mortality. MicroRNAs (miRNAs) participate in this response, but their
expression pattern and their role as biomarkers in CAP have not been fully characterized.
Methods
A prospective observational study was performed in a cohort of 153 consecutive patients
admitted to hospital with CAP. Clinical and analytical variables were collected, and the main
outcome variable was 30-day mortality. Small RNA was purified from plasma of these
patients obtained on the first day of admission, and miRNA expression was analyzed by RT-
PCR. Univariate and multivariate analyses were carried out through the construction of a
logistic regression model. The proposed model was compared with established prognostic
clinical scales using ROC curve analysis.
Results
The mean age of the patients included was 74.7 years [SD 15.9]. Their mean PSI was 100.9
[SD 34.6] and the mean modified Charlson index was 2.9 [SD 3.0]. Both miR-146a and miR-
16-5p showed statistically significant association with 30-day mortality after admission due
to CAP (1.10 vs. 0.23 and 51.74 vs. 35.23, respectively), and this association remained for
miR-16-5p in the multivariate analysis adjusted for age, gender and history of bronchoas-
piration (OR 0.95, p = 0.021). The area-under-the-curve (AUC) of our adjusted multivariate
model (AUC = 0.954 95%CI [0.91–0.99]), was better than those of prognostic scales such
as PSI (AUC = 0.799 [0.69–0.91]) and CURB-65 (AUC = 0.722 [0.58–0.86]).
PLOS ONE







Citation: Galván-Román JM, Lancho-Sánchez Á,
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Conclusions
High levels of miR-146a-5p and miR-16-5p upon admission due to CAP are associated with
lower mortality at 30 days of follow-up. Both miRNAs could be used as biomarkers of good
prognosis in subjects hospitalized with CAP.
Introduction
Community-acquired pneumonia (CAP) is a frequent and severe infection. Low tract respira-
tory infections are the fifth cause of overall mortality and the first infectious cause of mortality
worldwide [1, 2]. In addition to its impact on survival, suffering from CAP affects post-episode
quality of life and functionality [3], which represents a considerable burden on the health sys-
tem [4].
Numerous strategies have been studied to improve the prediction of CAP prognosis, and
thus help in decision-making regarding the management of these patients [5]. Various widely
validated clinical scores have been developed, such as the Pneumonia Severity Index (PSI) [6]
or CURB-65 [7], capable of evaluating the clinical situation at the time of diagnosis and pre-
dicting its evolution. In parallel, several factors of the inflammatory response associated with
CAP have been studied as potential prognostic markers in these patients [8], such as procalci-
tonin, C-reactive protein (CRP) or leukocyte count, showing prognostic utility that was not
better than common clinical scales [9].
MicroRNAs (miRNAs) are small non-coding RNA molecules that have a complementary
antiparallel sequence to messenger RNAs (mRNAs). Their binding to specific mRNAs allows
post-transcriptional regulation of gene expression, blocking protein synthesis [10]. They can
be secreted to the extracellular milieu included in small extracellular vesicles called exosomes.
Through these exosomes or bound to transport proteins, miRNAs can travel in the blood-
stream and can be incorporated into other cells, thereby regulating their gene expression [11].
These molecules are very abundant, widely present in multiple tissues and biological fluids,
and have evolutionarily conserved sequences [12]. They play a role in processes such as embry-
onic development, cell death and proliferation, hematopoiesis, neurodevelopment, and meta-
bolic regulation [13, 14]. But perhaps one of their most important functions is their role in
regulating immunological processes, including the innate and adaptive immune response, the
development and differentiation of immune cells, and the prevention of autoimmune disor-
ders [15].
Regarding CAP pathophysiology, miRNAs can influence the development and function of
immune cells by blocking the translation of key proteins such as transcription factors or inter-
mediate molecules in cell receptor signaling cascades [16]. In addition, some miRNAs have
been identified as key players in modulating the immune response to severe bacterial infection,
by controlling neutrophil activation and recruitment and the chemotactic signal that initiates
the inflammatory process [17]. MiRNA determination in peripheral blood has been used for
the diagnosis of malignancies, cardiovascular diseases or autoimmune disorders [18]. More-
over, several studies have established the utility of circulating miRNAs in the diagnosis of sep-
sis [19] and in various specific infections (e.g. HIV, viral hepatitis or tuberculosis) [20].
However, there is limited scientific literature on the usefulness of these molecules as prog-
nosis markers in CAP.
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In an attempt to find more accurate prognostic predictive tools for CAP, our research
group set out to analyze the use of circulating microRNAs as prognostic biomarkers for mor-
tality in this disease.
Materials and methods
Prospective observational study in a cohort of 153 consecutive patients admitted for CAP in
2015 at a university hospital in Spain. Patients older than 18 years diagnosed with CAP in the
Emergency Room were included in the study. CAP was considered when patients presented
symptoms of lower respiratory tract infection together with the appearance of a new infiltrate
on a chest radiograph and the absence of an alternative diagnosis during follow-up, according
to the usual definition [21]. Sociodemographic and clinical variables, presence of comorbidi-
ties (individual and grouped, such as the modified Charlson index [22]), characteristics of the
infectious process (including the CAP severity indices CURB65 and PSI) and analytical and
radiological parameters at admission were collected. These patients underwent a blood test on
the first day of admission, and were treated according to the clinical practice guidelines in
force at that time [5]. The main outcome variable was 30-day mortality.
This cohort has been previously used in other studies, in the context of a larger research
project on prognostic biomarkers in CAP [23, 24]. All the data generated during this research
are openly available in the public repository of Zenodo.org [https://doi.org/10.5281/zenodo.
3930832]. Furthermore, the methodology followed can be found in the previously published
protocol [25].
Laboratory procedures
Small RNA was purified from patients´ 250 μl plasma samples by column-based protocol, and
retrotranscribed to cDNA (Exiqon’s miRCURY™ series kits, 4 μl of RNA in-put); synthetic
RNA controls were added in this process (spike-ins UniSP2, UniSp4 and UniSp5 before RNA
extraction, and UniSP6 before retrotranscription to cDNA). After cDNA was diluted 1:40, the
quality of the process was evaluated (QC control Panel) and only 117 samples passed the test
(A detailed explanation of the technical criteria used for the exclusion of samples in the quality
control process can be found in S1 Fig in S1 Appendix). Eight samples paired by age and gen-
der were selected (4 patients who had suffered a cardiovascular event or death during follow-
up and 4 who had not) and a panel of 752 human miRNAs was tested (miRCURY LNA™ Uni-
versal—Ready-to-Use Human Panel, Exiqon), in order to determine a preliminary pattern of
differential miRNA expression between patients with different CAP progression.
According to the preliminary data obtained, 25 candidate miRNAs were selected: 4
intended to be used as normalizers, 5 selected by statistical criteria (univariate association with
mortality) and 16 selected from an exhaustive bibliographic search on miRNAs, sepsis, inflam-
mation and / or cardiovascular disease, prioritizing those that appeared in a greater number of
publications and those related to respiratory diseases. RT-PCR was carried out in triplicate by
hybridization with double-stranded flurochrome (ExiLENT SYBR1 Green Master Mix) using
the C1000 Touch CFX384 thermocycler (Bio-Rad). A PCR efficiency of 2 was assumed.
The relative amount of each miRNA was calculated with ΔCt = CtmiRNA—CtUniSp2, and it
was later normalized using the GeNorm algorithm and the geometric mean of the most stable
miRNAs. The final data was calculated with the formula 2-ΔCt and the values were expressed as
the fold change (FC) of each miRNA with respect to UniSP2, as described by Marabita et al.
[26].
Only miRNAs whose Cts were less than 2 standard deviation (SD) above the average of the
least abundant spike-in, UniSp5, were taken into consideration for the analysis.
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Statistical analysis
For the descriptive analysis of the cohort, mean and SD were calculated for quantitative vari-
ables with equal variances, and median and interquartile range for quantitative variables with
unequal variances. Normality of data was assessed with the Kolmogorov-Smirnov test and
homoscedasticity with the Levene’s test. Qualitative variables were expressed as proportion
and total cases. The relationship of the different independent variables with the cumulative
incidence of the main dependent variable was analyzed using the Student’s t-test for quantita-
tive variables with equal or unequal variances, or the χ2 test or the Fisher’s exact test for quali-
tative variables, as appropriate. For the correlation analysis of the candidate miRNAs, the
Pearson´s test (represented as a heat-map) was used, followed by the Spearman´s correlation
test. Subsequently, a multivariate analysis was carried out by constructing a logistic regression
model (for 30-day mortality), in order to study possible confounding and intermediate vari-
ables. All p values� 0.05 were considered statistically significant, although another threshold
(p� 0.10) was used in the processes of variable selection, following the principle of parsimony.
Selection of the most parsimonious model was made with the Likelihood-Ratio test (LR test).
The predictive capacity of the estimated model as well as the comparison with established
scales was made using Receiver operator characteristic (ROC) curves and subsequent compari-
son between areas under the curve (AUC). In addition, net reclassification index (NRI) and
integrated discrimination index (IDI) were calculated. Statistical analysis was carried out using
Stata v15 and R v3.5.2.
Ethical principles
This study was previously approved by the Research Ethics Committee (REC) of Hospital Uni-
versitario de La Princesa and it was carried out following the ethical principles established in
the Declaration of Helsinki, recommendations related to Good Clinical Practice, and the legis-
lation in force regarding confidentiality. All the included patients were informed about the
study and signed the informed consent, which was an inclusion criterion in this study.
Results
A total of 153 patients were included in the study. Mean age was 75.7 years [SD 16.1], with a
greater proportion of men (58.2%, n = 86). Most had a previous history of smoking (65.1%,
n = 99), with a chronic obstructive pulmonary disease (COPD) prevalence of 31.4% (n = 48).
The most frequent cardiovascular risk factor was high blood pressure (58.2%, n = 89), and the
most frequent cardiovascular comorbidity was chronic heart failure (18.9%, n = 29). The mod-
ified Charlson index was 3.12 points [SD 2.9]. The severity of pneumonia was quantified using
the usual scales: average PSI index was 103 points [SD 35.2] and average CURB-65 index was
2.78 points [SD 1.1].
Analytical and radiological variables, as well as all the prognostic scales measured were
compared between surviving and deceased patients 30 days after admission. Results are shown
in Table 1 and S1 and S2 Tables in S1 Appendix. Eighteen patients died in the first 30 days
after admission (11.8%).
A blood sample was taken from all included patients upon admission. Small RNA was
extracted from plasma samples and after quality control evaluation, only 117 samples were
considered valid for miRNA analysis. A flowchart of the detailed technical criteria for exclu-
sion of samples can be found in S1 Fig in S1 Appendix.
To assess whether sample exclusion was random, the main sociodemographic and clinical
variables were compared between the group of 117 patients with valid samples and the group
PLOS ONE Circulating miR-146a and miR-16-5p as prognostic biomarkers in CAP
PLOS ONE | https://doi.org/10.1371/journal.pone.0240926 October 23, 2020 4 / 13
Table 1. Sociodemographic variables and comorbidities.
TOTAL n = 153 30-day mortality p�
ALIVE n = 135 DECEASED n = 18
% n % n % n
Age—mean / SD 75.68 16.13 73.82 16.18 89.69 5.15 <0.001
Gender (male) 58.17 89 58.52 79 55.56 10 0.811
Ethnicity (caucasian) 97.39 149 97.04 131 100 18 1.000
Life habits and vaccination
Alcoholism (active o former) 8.50 13 8.89 12 5.56 1 1.000
Tobacco use (active o former) 65.10 99 65.93 89 58.82 10 0.563
Pack-years—mean / SD 27.24 29.66 27.17 29.37 27.86 33.38 0.935
Pneumococcal vaccination 41.33 62 40.60 54 47.06 8 0.611
Flu vaccination (previous year) 62.00 93 62.41 83 58.82 10 0.774
Comorbidities
HBP 58.17 89 59.26 80 50.00 9 0.454
DM 16.34 25 17.04 23 11.11 2 0.739
Hypercholesterolemia 32.68 50 30.37 41 50.00 9 0.095
Obesity 42.48 65 42.96 58 38.89 7 0.743
TIA 4.58 7 3.7 5 11.11 2 0.192
Stroke 11.76 18 9.63 13 27.78 5 0.041
Ischemic cardiomyopathy 8.5 13 7.41 10 16.67 3 0.183
Chronic heart failure 18.95 29 18.52 25 22.22 4 0.750
VTE 1.96 3 1.48 2 5.56 1 0.315
CKD 14.38 22 14.81 20 11.11 2 1.000
Chronic hapatopathy 3.27 5 3.7 5 0.00 0 0.406
COPD 31.37 48 31.85 43 27.78 5 0.794
Asthma 5.23 8 5.93 8 0.00 0 0.597
HIV infection 5.88 9 6.67 9 0.00 0 0.600
Solid neoplasm 9.15 14 8.15 11 16.67 3 0.216
Modified Charlson Index—mean / SD 3.12 2.94 2.98 2.98 4.22 2.39 0.092
Chronic treatment
Bronchodilators (any type) 33.33 51 34.07 46 27.78 5 0.791
Oral corticosteroids 3.97 6 3.73 5 5.88 1 0.518
Statins 29.14 44 28.36 38 35.29 6 0.553
Antiplatelets 26.14 40 25.19 34 33.33 6 0.460
Functional status
Institutionalized 7.84 12 5.93 8 22.22 4 0.037
Cognitive impairment 17.65 27 11.85 16 61.11 11 <0.001
Malnutrition 11.11 17 9.63 13 22.22 4 0.119
History of bronchoaspiration 8.5 13 4.44 6 38.89 7 <0.001
CKD: Chronic kidney disease; COPD: Chronic obstructive pulmonary disease; DM: Diabetes mellitus; HBP: High blood pressure; HIV: Human immunodeficiency
virus; TIA: Transient ischemic attack; VTE: Venous thromboembolism.
Quantitative variables: Mean and SD; Qualitative variables: % and n;
� Qualitative variables: Chi-square test or Fisher´s exact test. Quantitative variables: t-test for equal or unequal variances as appropriate.
https://doi.org/10.1371/journal.pone.0240926.t001
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of 36 patients excluded. No statistically significant differences were found (p�0.05) (S3
Table in S1 Appendix).
Analyzing the main outcome variable among those 117 patients with a valid sample, 11
patients (9.4%) died during the 30 days after admission for CAP.
Not all the microRNAs selected as candidates for analysis were measurable with guarantees
in the set of 117 patients; of the 25 candidate miRNAs, 11 were excluded from the final analysis
as they were not abundant enough in one or more patients (S4 Table in S1 Appendix). Four
miRNAs were used as normalizers (miR-103a-3p, miR-23b-3p, miR-23a-3p and miR -25-3p).
Association of normalized expression of each miRNA (FCs) with to 30-days mortality was
analyzed (Table 2).
MiR-16-5p and miR-146a levels were both significantly higher in patients who survived
compared to those who died after 30 days of follow-up (p = 0.010 and p<0.001, respectively).
Distribution of these miRNAs according to mortality is shown in Fig 1.
Next, we analyzed whether the expression of both candidate miRNAs showed correlation.
Heatmap representation of correlations between normalized relative quantities of the candi-
date miRNAs showed that miR-16-5p expression did not show a strong correlation with miR-
146a, although it correlated with three other miRNAs (miR-106-5p, miR-486p and miR-144-
3p; Fig 2). Moreover, a direct analysis of the correlation between miR-146a and miR-16-5p
showed a weak correlation (rho = -0.57, p<0.001).
Subsequently, to assess the prognostic power of both selected miRNAs, a multivariate
model was constructed through a logistic regression. For this analysis, all variables with
p�0.10 in the univariate analysis were included, as well as variables of clinical significance
such as sex or comorbidity assessed bymodified Charlson index. The PSI and CURB65 prog-
nostic scales were excluded from the model, since they were constructed from variables already
included in the multivariate analysis, and also to be able to later compare them with the fitted
model.
Finally, after comparing the models using the LR test, and always keeping in the model the
two significant miRNAs from the univariate analysis, the most parsimonious model was
Table 2. miRNA relative levels according to 30-day mortality.
microRNAs Total (n = 117) 30-day mortality p�
No (n = 106) Yes (n = 11)
mean SD mean SD mean SD
hsa-miR-107 0.17 0.08 0.17 0.08 0.19 0.09 0.343
hsa-miR-17-5p 0.67 0.23 0.69 0.22 0.56 0.27 0.074
hsa-miR-21 3.00 1.42 2.97 1.45 3.26 1.05 0.529
hsa-miR-144-3p 4.08 3.98 4.04 4.06 4.46 3.17 0.740
hsa-miR-16-5p 50.19 40.26 51.74 41.76 35.23 14.91 0.010
hsa-miR- 486 1.29 1.24 1.32 1.29 0.99 0.63 0.159
hsa-miR-20a 0.65 0.29 0.67 0.28 0.52 0.38 0.099
hsa-miR-34a-3p 0.02 0.03 0.01 0.03 0.03 0.05 0.223
hsa-miR-106b-5p 2.01 1.19 2.02 1.23 1.88 0.70 0.709
hsa-miR-146a 1.02 1.78 1.10 1.85 0.23 0.14 <0.001
hsa-miR-483-5p 0.02 0.04 0.01 0.04 0.04 0.08 0.285
hsa-miR-125b 0.03 0.06 0.03 0.04 0.07 0.17 0.453
� t-test for equal or unequal variances, as appropriate.
https://doi.org/10.1371/journal.pone.0240926.t002
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constructed with the variables age, sex, history of bronchoaspiration, miR-146a and miR-16-
5p (Table 3).
MiR-16-5p maintained statistical significance as a prognostic marker; based on the esti-
mated OR, it could be interpreted that for each decrease of one unit of miR-16-5p the probabil-
ity of survival would increase 1.05 folds. This model presents a high LR Test (χ2 = 41.231; p
<0.001), and good predictive capacity (R2Cox & Snell = 0.297; R2Nagalkerke = 0.640). Moreover, it
is superior to the unadjusted multivariate model (χ2 = 14.887; p = 0.001), with lower general-
ized coefficients of determination (R2Cox & Snell = 0.119 and R2Nagalkerke = 0.258).
Lastly, the predictive capacity for 30-day mortality of both models and the validated prog-
nosis clinical scales was assessed by ROC curve analysis (Fig 3).
The prognostic capacity of the adjusted model (AUC = 0.954 95%CI [0.91–0.99]), was bet-
ter than the unadjusted model (AUC = 0.824 [0.73–0.92]), and likewise better than the prog-
nostic scales PSI (AUC = 0.799 [0.69–0.91]) and CURB-65 (AUC = 0.722 [0.58–0.86]).
In addition, we sought to test how the model proposed could classify patients according to
30-day mortality compared to classic prognosis scales such as CURB-65 and PSI. For that pur-
pose, NRI and IDI were assessed. The NRI estimated for our multivariate model vs CURB-65
Fig 1. Relative expression levels (FCs) at admission of miR-16-5p (A) and miR-146a (B) according to 30-day
mortality after hospitalization for CAP. Data are represented as box plots. Dots represent outliers. Differences were
analyzed by Student´s t test for unequal variances p values� 0.05 are considered statistically significant.
https://doi.org/10.1371/journal.pone.0240926.g001
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was 59.61% (SE = 1391.69; p = 1) and vs PSI was 39.54% (SE = 1029.78; p = 1); IDI estimation
for our model vs. CURB-65 was -0.40 (SE = 0.12; p = 0.007) and vs. PSI was -0.41 (SE = 0.11;
p = 0.004).
Discussion
The present study tries to assess the utility of circulating microRNA levels as prognostic bio-
markers in patients admitted to hospital for CAP. For the selection of candidates, a two-step
study was performed, with a first global approach using microarrays, together with a selection
based on previous literature, followed by a second confirmation stage using semi-quantitative
RT-PCR. After analysis of twenty-five candidate miRNAs, only two of them, miR-146a and
miR-16-5p, showed a statistically significant association with mortality 30 days after admission
for CAP. High levels of both miRNAs were associated with greater survival. This association
Fig 2. Heatmap representation of correlations between miRNAs in plasma of CAP patients. Graphic represents
correlation between plasma levels of different miRNAs in CAP patients at admission. Correlation coefficients are
represented by a color scale. Red colors represent positive correlations and blue colors negative correlations. Darker
hues present higher coefficients. Squares outlined in black show the correlation between miR-146a and miR-16-5p.
https://doi.org/10.1371/journal.pone.0240926.g002
Table 3. Multivariate models of selected miRNAs, non-adjusted or adjusted for confounding variables.
NON-ADJUSTED MULTIVARIATE MODEL MULTIVARIATE MODEL ADJUSTED FOR
CONFOUNDING VARIABLES
OR 95% CI OR p OR 95% CI OR p
miR-16-5p 0.97 0.94-0.99 0.025 0.95 0.91-0.99 0.021
miR-146a 0.04 0.00-0.81 0.036 0.05 0.00-2.00 0.109
Age 1.36 1.05-1.77 0.022
Sex 0.09 0.001-1.50 0.093
History of bronchoaspiraton 36.49 1.48-899.17 0.028
Sex (female vs male), History of bronchoaspiration (yes vs no).
https://doi.org/10.1371/journal.pone.0240926.t003
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remained for miR-16-5p in the multivariate analysis after adjusting for age, gender, and history
of bronchoaspiration. In our sample of patients admitted with CAP, this adjusted model was at
least as good at predicting mortality at 30 days as the classic CURB-65 and PSI prognostic
scales, after comparison of AUCs and evaluation of reclassification indices NRI and IDI.
Therefore, and waiting to standardize the method and replicate it in other cohorts, our results
show that the measurement of miR-146a and miR-16-5p could be useful for predicting short-
term mortality after admission for CAP.
The use of circulating miRNAs as biomarkers is not new, and although is not yet wide-
spread as routine clinical practice, it has been successfully applied in the field of respiratory
diseases [27].
Regarding diagnosis, some authors have studied in depth the use of miRNAs as biomarkers
for pneumonia with respect to other respiratory diseases. For this purpose miRNA levels have
been determined in various biological fluids: in serum, allowing patients with pulmonary
tuberculosis to be distinguished from healthy controls and patients with CAP [28]; in exo-
somes from pleural fluid, distinguishing between CAP and lung cancer [29]; or in sputum, dis-
criminating active pulmonary tuberculosis from other diseases [30]. Within pneumonias, the
determination of circulating miRNAs has allowed differentiating viral pneumonia from bacte-
rial pneumonia in pediatric population [31]. It has also been used in the adult population, dif-
ferentiating bacterial etiology (Streptococcus pneumoniae) from viral etiology (Influenza H3N2
virus) [32]. Interestingly, apart from studies in respiratory diseases, miR-146a determination
in plasma has been successfully used as a diagnostic biomarker of sepsis in patients with clini-
cal criteria for systemic inflammatory response syndrome (SIRS) [33].
Regarding prognosis, few studies have evaluated the ability of these molecules to predict
disease progression. Wu et al. found that elevated miR-146a, miR-27a, miR-126, and miR-155
in serum exosomes were associated with increased occurrence of acute respiratory distress
syndrome in patients with CAP; they even concluded that miR-126 could be used as a prog-
nostic marker, as it was statistically associated with 28-day mortality [34]. In another recent
article, Zhang et al., using a sepsis-specific preloaded microarray concluded that miR-223-3p
could be used to predict the development of sepsis in CAP [35]. As far as we know, there are
no other studies–in the literature that have investigated the use of the determination of circu-
lating miRNAs levels to evaluate CAP prognosis.
Fig 3. ROC curve analysis of non-adjusted and adjusted multivariate models and common CAP severity scales
PSI y CURB-65 for 30-day mortality.
https://doi.org/10.1371/journal.pone.0240926.g003
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Our finding of lower 30-day mortality in patients with elevated levels of miR-16-5p and
miR-146a at admission for CAP could reflect a better inflammatory response against the
invading pathogen.
MiR-16-5p has been linked to mechanisms of protection from lung damage after infection.
In cell models subjected to lipopolysaccharide (LPS)-induced damage, overexpression of miR-
16-5p reduced acute lung damage through inhibition of the systemic inflammatory response
via inhibition of TNF-α and interleukin-6 [36]. These results have subsequently been repli-
cated in an animal model of chronic lung infection with Mycoplasma gallisepticum; overex-
pression of miR-16-5p was able to stop the inflammatory response, exerting its inhibitory
effect directly on PI3K kinase, which is a key component in the NF-κB activation cascade, and
therefore, for TNF-α production [37].
Likewise, elevated miR-146a levels have been associated with reduction of LPS induced
lung inflammation: exogenous addition of miR-146a significantly suppress LPS-induced
inflammatory response (TNF-α, IL-6, and IL-1β expression) in alveolar macrophages, through
inhibition of IRAK-1 and TRAF-6 expression, both key components of the NF-κB activation
cascade [38].
Interestingly, in murine models of pneumococcal pneumonia, exogenous mimetic miRNAs
that inhibit this pathway—such as miR 124 3p [39] and miR-302 [40]—promote the regenera-
tion of alveolar epithelial cells and improve the recovery of mice affected by bacterial
pneumonia.
Thus, a physiopathogenic explanation of the protective effect of circulating miR-16-5p and
miR-146a observed in our patients could be related to their inhibitory effect on the inflamma-
tory response. High levels of both miRNAs detected in CAP patients upon admission could be
involved in reducing activation of the inflammatory cascades secondary to lung infection,
thereby decreasing systemic inflammatory burden, and allowing a better clinical evolution in
the medium term.
Furthermore, these results would be in line with those already published by our research
group showing that uncontrolled inflammation in CAP and its quantification by means of
blood markers allows predicting adverse prognosis in short and medium term follow-up [23,
24, 41].
We consider that the main weaknesses of our study are the difficult standardization of
miRNA quantification, a common problem in this type of studies, and the exclusive recruit-
ment of hospitalized patients, which makes it difficult to compare our miRNA data with widely
used prognostic scales.
The main strengths are the sample size reached, which was sufficient to achieve statistically
significant results, the use of strict quality criteria in the selection of valid samples, the use of
various endogenous and exogenous miRNAs in the standardization process, and above all, the
selection process of miRNAs in two steps, which ensured a good initial selection of candidates.
Nevertheless, the prognostic value of miR-16-5p and miR-146a described in this work
needs to be further confirmed in routine clinical practice.
Conclusions
In CAP patients requiring hospitalization, elevated plasma levels of miR-146a-5p and miR-16-
5p measured at admission are associated with lower mortality at 30 days of follow-up. These
two miRNAs could be used in the future as biomarkers of good prognosis in patients hospital-
ized for CAP.
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Resources: Mara Ortega-Gómez.
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